Journal of Clinical Pharmacy and Therapeutics

Editors

A. Li Wan Po and M. J. Kendall

Volume 27
2002

Blackwell
Publishing

© 2002 Blackwell Science

Published by Blackwell Publishing Ltd
Osney Mead, Oxford OX2 0EL
108 Cowley Road, Oxford OX4 1JF
23 Ainslie Place, Edinburgh EH3 6AJ
Commerce Place, 350 Main Street, Malden, MA 02148-5018, USA
550 Swanston Street, Carlton South, Victoria 3053, Australia

Other Editorial Offices:
Blackwell Publishing France Ltd, 10 rue Casimir Delvigne, 75006, Paris, France
Blackwell Munksgaard, 1, Rosenøms Allè, PO Box 227, DK-1502 Copenhagen V, Denmark
Blackwell Verlag, Kurfüstendam 57, D-10707 Berlin, Germany
Blackwell Publishing KK, Healthcare Division, NK Bldg, 3F, 2-8-12 Iwamotocho, Chiyodaku, Tokyo 101-0032, Japan

All rights reserved. With the exception of fair dealing for the purposes of research or private study, or criticism or review, no part of this publication may be reproduced, stored or transmitted in any form or by any means without the prior permission in writing from the copyright holder. Authorization to photocopy items for internal and personal use is granted by the copyright holder for libraries and other users of the Copyright Clearance Center (CCC), 222 Rosewood Drive, Danvers, MA 01923, USA (www.copyright.com), provided the appropriate fee is paid directly to the CCC. This consent does not extend to other kinds of copying, such as copying for general distribution for advertising or promotional purposes, for creating new collective works or for resale. Special requests should be addressed to the Editor, *Journal of Clinical Pharmacy and Therapeutics*, ISSN 0269-4727/02 $15.00.

Journal of Clinical Pharmacy and Therapeutics is covered by Current Contents/Clinical Medicine, Medline, EMBASE (Excerpta Medica), Science Citation Index, ADONIS, BIOSIS, CINAHL.

ISSN 0269–4727

Typeset by SPS (Chennai), India
Printed by Cambrian Printers, Aberystwyth, UK

CONTENTS

NUMBER 1

Commentaries

1 The heart protection study: statins for all those at risk?: *M. J. Kendall and S. L. Nuttall*

5 Digoxin-drug interactions: study design and generalizability: *A. Li Wan Po*

Research and Reports

7 Absence of a pharmacokinetic interaction between digoxin and levofloxacin: *S.-C. Chien, M. C. Rogge, R. R. Williams, J. Natarajan, F. Wong and A. T. Chow*

13 Effects of the concomitant administration of tamsulosin (0·8 mg) on the pharmacokinetic and safety profile of intravenous digoxin (Lanoxin®) in normal healthy subjects: a placebo-controlled evaluation: *Y. Miyazawa, L. P. Starkey, A. Forrest, J. J. Schentag, H. Kamimura, H. Swarz and Y. Ito*

21 Assessment of new onset postcoronary artery bypass surgery atrial fibrillation: current practice pattern review and the development of treatment guidelines: *A. E. Thompson, G. M. Hirsch and G. J. Pearson*

39 Compatibility of ropivacaine with morphine, sufentanil, fentanyl, or clonidine: *K. Öster Svedberg, J. McKenzie and C. Larrivee-Elkins*

47 Identifying patient and physician characteristics that affect compliance with antihypertensive medication: *X. S. Ren, L. E. Kazis, A. Lee, H. Zhang and D. R. Miller*

57 Determinants of physicians' attitude towards prescribing: *Y. T. Wun, C. S. Y. Chan and J. A. Dickinson*

Research Note

67 Using case-control studies for prescribing research: *J. Mant and M. Vessey*

Case Report

75 Gynecomastia with sulpiride: *Y. Kaneda and A. Fujii*

NUMBER 2

Commentary

79 Application of dynamic laser scattering to the quality control of injectable drugs: polymer formation in ampicillin solution: *T. Sendo, D. Teshima, K. Makino, K. Mishima, Y. Itoh and R. Oishi*

Research and Reports

85 Heart rate variability – a therapeutic target?: *H. C. Routledge, S. Chowdhary and J. N. Townend*

93 Use of night-time benzodiazepines in an elderly inpatient population: *M. Ramesh and G. Roberts*

99 Differential tramadol and *O*-desmethyl metabolite levels in brain vs. plasma of mice and rats administered tramadol hydrochloride orally: *Q. Tao, D. J. Stone, M. R. Borenstein, E. E. Codd, T. P. Coogan, D. Desai-Krieger, S. Liao and R. B. Raffa*

107 Laxative prescribing in relation to opioid use and the influence of pharmacy-based intervention: *M. L. Bouvy, H. Buurma and T. C. G. Egberts*

111 Nomogram for individualizing supplementary iron doses during erythropoietin therapy in haemodialysis patients: *K. Kadota, K. Kamata, Y. Kobayashi, H. Kagaya, S. Shimada, K. Yoshimoto-Furuie and H. Echizen*

121 Relationship of serum ACE inhibition to oral dose of enalapril in normotensive volunteers: *M. Rouini, M. Hamidi, A. Ghayoumi and A. Ismailpour*

127 Cost analysis of fentanyl and remifentanil in coronary artery bypass graft surgery without cardiopulmonary bypass: *P. Reddy, B. M. Feret, L. Kulicki, S. Donahue and R. A. Quercia*

133 Experience with use of recombinant activated factor VII: *F. Divanon, C. Hecquard and A. Borel-Derlon*

139 Leaching of diethylhexyl phthalate from polyvinyl chloride bags into intravenous etoposide solution: *B. Demoré, J. Vigneron, A. Perrin, M. A. Hoffman and M. Hoffman*

143 Penetration of levofloxacin into skin tissue after oral administration of multiple 750 mg once-daily doses: *A. T. Chow, A. Chen, H. Lattime, N. Morgan, F. Wong, C. Fowler and R. R. Williams*

Research Note

151 The contribution of cohort studies to prescribing research: *J. A. Simpson and P. C. Hannaford*

NUMBER 3

Commentaries

157 Aspirin and Reye's syndrome: is the response appropriate?: *N. J. Langford*

161 Indirect modulation of dopamine D2 receptors as potential pharmacotherapy for schizophrenia: III. Retinoids: *A. Schock Citver, A. M. Shields, L. M. Ciaccia, R. J. Schulingkamp and R. B. Raffa*

Review Article

169 Potential novel targets for Alzheimer pharmacotherapy: I. Secretases: *A. F. Maiorini, M. J. Gaunt, T. M. Jacobsen, A. E. McKay, L. D. Waldman and R. B. Raffa*

Research and Reports

185 Co-phenylcaine as an alternative to Brompton's solution in rigid nasendoscopy: a pilot study: *P. Walshe, H. Rowley, S. Hone and C. Timon*

189 Bayesian population model of methotrexate to guide dosage adjustments for folate rescue in patients with breast cancer: *S. Monjanel-Mouterde, C. Lejeune, J. Ciccolini, N. Merite, D. Hadjaj, P. Bonnier, P. Piana and A. Durand*

197 Prescribing indicators and their use by primary care groups to influence prescribing: *M. Ashworth, S. Golding and A. Majeed*

205 Comparison of ceftazidime degradation in glass bottles and plastic bags under various conditions: *M. Arsène, P. Favetta, B. Favier and J. Bureau*

211 The single nucleotide polymorphism T1128C in the signal peptide of neuropeptide Y (NPY) was not identified in a Korean population: *B. Ding, L. Bertilsson and C. Wahlestedt*

213 Variation in pharmacy prescription refill adherence measures by type of oral antihyperglycaemic drug therapy in seniors in Nova Scotia, Canada: *B. A. Morningstar, I. S. Sketris, G. C. Kephart and D. A. Sclar*

221 The effects on GP prescribing of joining a commissioning group: *M. Ashworth, D. Armstrong, D. Lloyd and S. Colwill*

Letter to the Editor

229 Paeoniae Radix, a traditional Chinese medicine, and CYP2C9 activity: *H.-J. Xie, Ü. Yasar, M. Sandberg and A. Rane*

231 Erratum

NUMBER 4

Review Article

233 The cardioprotective role of β-blockers in patients with diabetes mellitus: *M. J. Landray, V. Toescu and M. J. Kendall*

Research and Reports

243 Patients' knowledge and perceptions of the side-effects of OTC medication: *L. Hughes, C. Whittlesea and D. Luscombe*

249 Validation of an instrument to assess patient attitudes towards prescribing of pharmaceuticals by doctors: *C. S. Y. Chan, W. E. Fabb and C. B. Hazlett*

257 Predictive performance of serum digoxin concentration in patients with congestive heart failure by a hyperbolic model based on creatinine clearance: *H. Konishi, S. Shimizu, M. Chiba, T. Minouchi, M. Koida and A. Yamaji*

267 Beneficial effect of replacing of angiotensin-converting enzyme inhibitor with angiotensin II antagonist for heart failure patients: *Y. Hara, M. Hamada, Y. Shigematsu, T. Ohtsuka and K. Hiwada*

273 Health professionals' and consumers' views on the role of the pharmacy personnel and the pharmacy service in Hanoi, Vietnam – a qualitative study: *E. Olsson, L. T. N. Tuyet, H. A. Nguyen and C. Stålsby Lundborg*

281 Pharmacokinetics and pharmacodynamics of methylprednisolone after one bolus dose compared with two dose fractions: *A. Uhl, D. Czock, B.-O. Boehm, D. Zellner, A. Mertz and F. Keller*

289 Treatment of upper respiratory tract infections – a comparative study of dispensing and non-dispensing doctors: *B. Trap and E. H. Hansen*

Research Note

299 Segmented regression analysis of interrupted time series studies in medication use research: *A. K. Wagner, S. B. Soumerai, F. Zhang and D. Ross-Degnan*

NUMBER 5

Commentary

311 Re: GPs' views on computerized drug interaction alerts: *M. Ashworth*

Review Articles

313 Microtubules: dynamics, drug interaction and drug resistance in *Leishmania*: *K. G. Jayanarayan and C. S. Dey*

321 Current concepts in cyclooxygenase inhibition in breast cancer: *G. Singh-Ranger and K. Mokbel*

Research and Reports

329 Relationship between sample size and the definition of equivalence in non-inferiority drug studies: *J. A. Millar and V. Burke*

335 Development of a Canadian family medicine pharmacy practice experience programme: *A. M. Whelan*

343 A systematic review of tegaserod for the treatment of irritable bowel syndrome: *B. W. Jones, D. J. Moore, S. M. Robinson and F. Song*

353 Quantification of *Helicobacter pylori* resistance in functional and organic dyspepsia: *M. Rosandić, V. Pilaš, M. Bevanda, V. Fališevac and B. Korać*

357 Drug utilization pattern of anti-epileptic drugs: a pharmacoepidemiologic study in Oman: *Y. Hanssens, D. Deleu, K. Al Balushi, A. Al Hashar and I. Al-Zakwani*

365 Voltammetric determination of nitrosocimetidine in simulated gastric juice: *M. I. Walash, F. Belal, F. Ibrahim, M. Hefnawy and M. Eid*

371 Myocardial infarction and type II diabetes – preferential treatment for high risk patients?: *B. Green, S. Duffull, N. Cottrell and M. D'Emden*

377 GPs' views on computerized drug interaction alerts: questionnaire survey: *D. Magnus, S. Rodgers and A. J. Avery*

Research note

383 Using effectiveness studies for prescribing research, part 1: *N. Freemantle and J. Eastaugh*

NUMBER 6

Review Article

391 Herbal medication: potential for adverse interactions with analgesic drugs: *W. Abebe*

Research and Reports

403 Simple and simultaneous determination of sulphapyridine and acetylsulphapyridine in human serum by column-switching high-performance liquid chromatography: *D. Teshima, B. Hino, Y. Itoh and R. Oishi*

409 Comparative efficacy of a proprietary topical ibuprofen gel and oral ibuprofen in acute soft tissue injuries: a randomized, double-blind study: *M. Whitefield, C. J. A. O'Kane and S. Anderson*

419 Population pharmacokinetics of intravenous valproic acid in Korean patients: *H.-M. Park, S.-S. Kang, Y.-B. Lee, D.-J. Shin, O.-N. Kim, S.-B. Lee and D.-S. Yim*

427 Effect of vigabatrin on the pharmacokinetics of carbamazepine: *A. Sánchez-Alcaraz, M[a]. B. Quintana, E. López, I. Rodríguez and P. Llopis*

431 Ethical dilemmas in antibiotic prescribing: analysis of everyday practice: *I. Björnsdóttir and E. H. Hansen*

441 Patient characteristics and prescription patterns of atypical antipsychotics among patients with schizophrenia: *X. S. Ren, L. E. Kazis, A. F. Lee, A. Hamed, Y. H. Huang, F. Cunningham and D. R. Miller*

453 Diazoxide in the treatment of schizophrenia: novel application of potassium channel openers in the treatment of schizophrenia: *S. Akhondzadeh, V. Mojtahedzadeh, G.-R. Mirsepassi, M. Moin, H. Amini-Nooshabadi and A. Kamalipour*

461 Effect of proguanil interaction on bioavailability of cloxacillin: *C. P. Babalola, G. B. Iwheye and A. A. Olaniyi*

Case Report

465 Alternative venlafaxine kinetics in overdose: *N. J. Langford, U. Martin, M. Ruprah and R. E. Ferner*

Research Note

469 Using effectiveness studies for prescribing research, part 2: *N. Freemantle and J. Eastaugh*

475 Author and keyword Index